Growth Hormone Therapy and Leukaemia

Overview

Journal Eur J Pediatr

Specialty Pediatrics

Date 1989 Jun 1

PMID 2663511

Citations 8

Authors

N Stahnke

H J Zeisel

Affiliations

Soon will be listed here.

Abstract

Following an initial report from Japan in 1987, 15 growth hormone (GH)-deficient patients developed leukaemia during or following GH treatment. Nearly all available pituitary and biosynthetic growth hormones have been used. In 14 of these 15 patients GH treatment was initiated in 1975 or later with doses between 4.5 and 18IU/m2 per week. The therapy period was between 0.17 and 8.0 years. Leukaemia occurred 0.2-11 years after the start of GH treatment. GH affects normally and abnormally growing blood cells in vitro and in animal experiments, but the clinical data in humans do not indicate GH induction of tumour growth. Seven out of the 14 patients under discussion had an additional increased leukaemia risk. Two other patients had been treated only for a very short time. Though no clear evidence of a strikingly augmented leukaemia incidence in GH-treated patients is found worldwide, the available data call for increased attention.

Citing Articles

Cancer risk following growth hormone use in childhood: implications for current practice.

Ogilvy-Stuart A, Gleeson H Drug Saf. 2004; 27(6):369-82.

PMID: 15144231 DOI: 10.2165/00002018-200427060-00002.

Malignant thymoma in a patient with growth hormone deficiency during growth hormone therapy.

Hasegawa T, Hasegawa Y, KOTO S, Aso T, Tsuchiya Y, Hayashi A Eur J Pediatr. 1993; 152(10):802-4.

PMID: 8223780 DOI: 10.1007/BF02073374.

Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone.

Tedeschi B, Spadoni G, Sanna M, Vernole P, Caporossi D, Cianfarani S Hum Genet. 1993; 91(5):459-63.

PMID: 7686129 DOI: 10.1007/BF00217772.

Leukaemia in children with growth hormone deficiency not treated with growth hormone.

Kubota M, Fujii K, Yamanaka C, Akiyama Y, Momoi T, Hori C Eur J Pediatr. 1995; 154(5):418-9.

PMID: 7641781 DOI: 10.1007/BF02072121.

Wilms tumour in a patient with growth hormone replacement therapy.

Momoi T, Yamanaka C, Yorifuji T, Sasaki H, Kaji M, Akiyama Y Eur J Pediatr. 1989; 149(3):159-61.

PMID: 2558888 DOI: 10.1007/BF01958269.

References

Najarian T, Colton T . Mortality from leukaemia and cancer in shipyard nuclear workers. Lancet. 1978; 1(8072):1018-20. DOI: 10.1016/s0140-6736(78)90741-9. View

Gutjahr P . [Secondary neoplasms following tumor and leukemia therapy in childhood. Report of 64 cases]. Dtsch Med Wochenschr. 1985; 110(42):1599-606. DOI: 10.1055/s-2008-1069053. View

Brown P . Human growth hormone therapy and Creutzfeldt-Jakob disease: a drama in three acts. Pediatrics. 1988; 81(1):85-92. View

Boice J . Cancer following medical irradiation. Cancer. 1981; 47(5 Suppl):1081-90. DOI: 10.1002/1097-0142(19810301)47:5+<1081::aid-cncr2820471305>3.0.co;2-3. View

Goujard J, Entat M, Maillard F, Mugnier E, Rappaport R, Job J . Human pituitary growth hormone (hGH) and Creutzfeldt-Jakob disease: results of an epidemiological survey in France, 1986. Int J Epidemiol. 1988; 17(2):423-7. DOI: 10.1093/ije/17.2.423. View

BIERICH J, Ramashastry R, Kracht J . [Current studies on the development of thymus hyperplasia]. Monatsschr Kinderheilkd (1902). 1967; 115(4):310-3. View

Clayton P, Price D, Shalet S, Gattemaneni H . Craniopharyngioma recurrence and growth hormone therapy. Lancet. 1988; 1(8586):642. DOI: 10.1016/s0140-6736(88)91434-1. View

Mike V, Meadows A, DAngio G . Incidence of second malignant neoplasms in children: results of an international study. Lancet. 1982; 2(8311):1326-31. DOI: 10.1016/s0140-6736(82)91524-0. View

Rogers P, Komp D, Rogol A, Sabio H . Possible effects of growth hormone on development of acute lymphoblastic leukaemia. Lancet. 1977; 2(8035):434-5. DOI: 10.1016/s0140-6736(77)90613-4. View

10.

Talwar G, Pandian M, Kumar N, Hanjan S, Saxena R, Krishnaraj R . Mechanism of action of pituitary growth hormone. Recent Prog Horm Res. 1975; 31:141-74. DOI: 10.1016/b978-0-12-571131-9.50008-6. View

11.

Endo M, Kaneko Y, Shikano T, Minami H, Chino J . Possible association of human growth hormone treatment with an occurrence of acute myeloblastic leukemia with an inversion of chromosome 3 in a child of pituitary dwarfism. Med Pediatr Oncol. 1988; 16(1):45-7. DOI: 10.1002/mpo.2950160111. View

12.

Desai L, Lazarus H, Li C, FOLEY G . Human leukemic cells. Effect of human growth hormone. Exp Cell Res. 1973; 81(2):330-2. DOI: 10.1016/0014-4827(73)90522-3. View

13.

Gibson B, Eden O, Barrett A, Stiller C, Draper G . Leukaemia in young children in Scotland. Lancet. 1988; 2(8611):630. DOI: 10.1016/s0140-6736(88)90668-x. View

14.

Mosijczuk A, RUYMANN F . Second malignancy in acute lymphocytic leukemia. Review of 33 cases. Am J Dis Child. 1981; 135(4):313-6. DOI: 10.1001/archpedi.1981.02130280003002. View

15.

Kiess W, Butenandt O . Specific growth hormone receptors on human peripheral mononuclear cells: reexpression, identification, and characterization. J Clin Endocrinol Metab. 1985; 60(4):740-6. DOI: 10.1210/jcem-60-4-740. View

16.

Ericsson J, Karnstrom L, Mattsson B . Childhood cancer in Sweden, 1958-1974. I. Incidence and mortality. Acta Paediatr Scand. 1978; 67(4):425-32. DOI: 10.1111/j.1651-2227.1978.tb16349.x. View

17.

Young Jr J, Miller R . Incidence of malignant tumors in U. S. children. J Pediatr. 1975; 86(2):254-8. DOI: 10.1016/s0022-3476(75)80484-7. View

18.

HEYSSEL R, Brill A, WOODBURY L, NISHIMURA E, Ghose T, Hoshino T . Leukemia in Hiroshima atomic bomb survivors. Blood. 1960; 15:313-31. View

19.

Astaldi Jr A, Yalcin B, MEARDI G, Burgio G, Merolla R, ASTALDI G . Effect of growth hormone on lymphocyte transformation in cell culture. Blut. 1973; 26(1):74-81. DOI: 10.1007/BF01631315. View

20.

Li F . Second malignant tumors after cancer in childhood. Cancer. 1977; 40(4 Suppl):1899-902. DOI: 10.1002/1097-0142(197710)40:4+<1899::aid-cncr2820400821>3.0.co;2-u. View